^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    11h
    A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=42, Terminated, Prelude Therapeutics | Trial completion date: Apr 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date • First-in-human
    2d
    NRG-GI007: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, NRG Oncology | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    carboplatin • paclitaxel • Telomelysin (suratadenoturev)
    5d
    Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Duke University | N=500 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    6d
    A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=101, Recruiting, Kyowa Kirin Co., Ltd. | N=71 --> 101 | Trial completion date: Dec 2027 --> Mar 2029 | Trial primary completion date: Dec 2027 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    docetaxel
    10d
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, LaNova Medicines Limited
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    10d
    DRAGON - IV: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov)
    P2/3, N=580, Active, not recruiting, Ruijin Hospital | Trial completion date: Aug 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    11d
    Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=51, Recruiting, Oscotec Inc.
    New P1 trial
    |
    docetaxel • OCT-3598
    12d
    CAMILLA: Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (clinicaltrials.gov)
    P1/2, N=117, Recruiting, Anwaar Saeed | Trial completion date: Jan 2028 --> Jun 2029 | Trial primary completion date: Jan 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    RAS wild-type
    |
    Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)
    13d
    Neoadjuvant Treatment Modalities in Esophageal Cancer (clinicaltrials.gov)
    P3, N=2000, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • TheraCIM (nimotuzumab)
    13d
    Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer (clinicaltrials.gov)
    P3, N=2000, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • TheraCIM (nimotuzumab)
    18d
    Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. (PubMed, BMC Med)
    IBI389 showed manageable safety profiles in patients with advanced solid tumors and preliminary efficacy in Claudin18.2-positive patients with GC/GEJC.
    P1 data • Journal
    |
    CLDN18 (Claudin 18)
    |
    IBI-389
    20d
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397